Earnings Troubles May Signal Larger Issues for Pulike Biological Engineering (SHSE:603566) Shareholders
Earnings Troubles May Signal Larger Issues for Pulike Biological Engineering (SHSE:603566) Shareholders
A lackluster earnings announcement from Pulike Biological Engineering, Inc. (SHSE:603566) last week didn't sink the stock price. We think that investors are worried about some weaknesses underlying the earnings.
Pulike生物工程公司(SHSE:603566)上週發佈的平淡收益公告並未拖累股價。我們認爲投資者擔心一些基本盈利的弱點。
![big](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20241106/0-7b0a8249a9560348b7d76de46ca08efa-0-f5ddfc8e697b7b9fec5b8cee420b3a91.png/big)
The Impact Of Unusual Items On Profit
除了稀釋之外,還應該注意的是,萬集科技在過去12個月中因不尋常項目獲得了價值人民幣3.5萬元的利潤。雖然我們希望看到利潤增加,但當這些不尋常項目對利潤做出重大貢獻時,我們會更加謹慎。我們對全球大部分上市公司的數據進行了分析,發現不尋常項目往往是一次性的。這正如我們所期望的那樣,因爲這些提升被描述爲"不尋常"。相對於其利潤而言,萬集科技在2021年12月前的不尋常項目貢獻大。因此,我們可以推斷出,這些不尋常項目正在使其財務利潤顯著增強。
To properly understand Pulike Biological Engineering's profit results, we need to consider the CN¥13m gain attributed to unusual items. While it's always nice to have higher profit, a large contribution from unusual items sometimes dampens our enthusiasm. When we crunched the numbers on thousands of publicly listed companies, we found that a boost from unusual items in a given year is often not repeated the next year. Which is hardly surprising, given the name. If Pulike Biological Engineering doesn't see that contribution repeat, then all else being equal we'd expect its profit to drop over the current year.
爲了正確理解Pulike生物工程的利潤結果,我們需要考慮歸因於飛凡項目的1300萬元人民幣收益。儘管獲得更高的利潤總是不錯,但飛凡項目的大額貢獻有時會減弱我們的熱情。當我們對成千上萬家上市公司的數據進行分析時,我們發現在某一年獲得的飛凡項目增長通常在下一年不會重複。這並不奇怪,考慮到名稱。如果Pulike生物工程未能看到這項貢獻再次出現,那麼其他條件相同,我們預計其今年的利潤將下降。
That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates.
這可能會讓您想知道分析師對未來盈利能力的預測。幸運的是,您可以單擊此處查看基於其估計的未來盈利能力的互動圖表。
Our Take On Pulike Biological Engineering's Profit Performance
我們對Pulike生物工程的利潤表現的看法
Arguably, Pulike Biological Engineering's statutory earnings have been distorted by unusual items boosting profit. Therefore, it seems possible to us that Pulike Biological Engineering's true underlying earnings power is actually less than its statutory profit. Sadly, its EPS was down over the last twelve months. The goal of this article has been to assess how well we can rely on the statutory earnings to reflect the company's potential, but there is plenty more to consider. In light of this, if you'd like to do more analysis on the company, it's vital to be informed of the risks involved. To help with this, we've discovered 2 warning signs (1 is concerning!) that you ought to be aware of before buying any shares in Pulike Biological Engineering.
有人認爲,飛凡生物工程的法定收益已被提振盈利的異常項目扭曲。因此,對我們來說,飛凡生物工程真正的基礎盈利潛力實際上可能低於其法定利潤。遺憾的是,其每股收益在過去十二個月下降。本文的目標是評估我們是否能夠依靠法定收益來反映公司的潛力,但還有很多問題需要考慮。基於此,如果您想對公司進行更多分析,了解涉及的風險是至關重要的。爲了幫助分析,我們發現了2個警示信號(其中1個令人擔憂!)在購買飛凡生物工程的股票之前,您應該了解。
Today we've zoomed in on a single data point to better understand the nature of Pulike Biological Engineering's profit. But there is always more to discover if you are capable of focussing your mind on minutiae. Some people consider a high return on equity to be a good sign of a quality business. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks with high insider ownership.
今天,我們聚焦一個單一數據點,以更好地了解飛凡生物工程利潤的本質。但如果您能夠集中精力關注細枝末節,總會發現更多。一些人認爲高股淨收益率是優質企業的良好標誌。因此,您可能希望查看這個收集高股權報酬率公司的免費列表,或者查看這份擁有高內部持股的股票名單。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對這篇文章有反饋嗎?對內容感到擔憂嗎?請直接與我們聯繫。或者,發送電子郵件至editorial-team @ simplywallst.com。
Simply Wall St的這篇文章是一般性質的。我們僅基於歷史數據和分析師預測提供評論,使用公正的方法,我們的文章並非意在提供財務建議。這並不構成買入或賣出任何股票的建議,並且不考慮您的目標或財務狀況。我們旨在爲您帶來基於基礎數據驅動的長期聚焦分析。請注意,我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St對提及的任何股票都沒有持倉。